By fully incorporating Informatics into the Department, we have developed the Cardiovascular Outcomes Research Enterprise and and Workflow Efficiency Tools.
The Cardiovascular Outcomes Research Enterprise is a collaborative effort of clinicians, nurses, statisticians, epidemiologists, researchers and scientists from Informatics to enable academic queries of clinical databases, comparative effectiveness evaluations, quality improvements and dashboards.
Workflow Efficiency Tools include real-time dashboards that facilitate OR scheduling, real-time reminders
and notifications and enhanced tools for electronic documentation.
In addition to studying new ways to surgically treat congenital and adult heart disease, we maintain a
national presence in several national clinical trials.
• The Department of Cardiac Surgery was chosen as only one of 15 major academic centers involved in the first NIH observational trial for hybrid coronary revascularization – the combination of
coronary stenting and bypass surgery.
• Vanderbilt was chosen to be part of the first U.S. trial of the CoreValve® transcatheter aortic-valve system (Medtronic, Minneapolis, MN).
• Vanderbilt was the largest enrolling site for the St. Jude Medical TrifectaTM Valve.
Vanderbilt is also participating in the PostApproval Study.
by Kathy Whitney | Posted on Monday, Aug. 15, 2011 | researchnews@Vanderbilt
The Department of Cardiac Surgery and the Division of Cardiology are collaborating on a study to better understand the genetic profile of mitral valve regurgitation.
Mitral valve regurgitation occurs when the mitral valve, which sits between the heart’s two left chambers, doesn’t close tightly, allowing blood to flow backward into the heart.
With the support of a Vanderbilt Institute for Clinical and Translational Research (VICTR) grant, Tarek Absi, assistant professor of cardiac surgery, and Yan Ru Su, director of the Cardiology Clinical and Translational Research Core Lab, are hoping to predict how patients with mitral valve disease will respond to current treatment, both medical and surgical, and to identify novel molecular targets for new treatment.
“We are a very busy cardiac surgery center with a high volume of mitral valve surgeries,” Absi said. “We want to use our resources at Vanderbilt to conduct basic science research in order to delineate how different mitral valve diseases are distinguished at the tissue, cellular and molecular level.”
Jim Atkinson, professor of pathology, is helping with pathological diagnosis and classification of the surgical tissue samples, which are collected when patients undergo mitral valve surgery.
We hope to add to the understanding of disease mechanism at the molecular level in order to develop a more comprehensive strategy for clinical treatment,” Su said.“Not much is known about the molecular pathophysiology of mitral valve disease. We hope to add to the understanding of disease mechanism at the molecular level in order to develop a more comprehensive strategy for clinical treatment,” Su said.
“The collaboration between Dr. Su and Dr. Absi is bench-to-bedside research at its best,” said Doug Sawyer, chief of the division of cardiovascular medicine.
John G. Byrne, William S. Stoney Professor of Cardiac Surgery and chair of the department, Steve Ball, assistant professor of cardiac surgery, and Michael Petracek, professor of clinical cardiac surgery, perform many of the valve repair procedures at Vanderbilt Heart.
“This research may allow us to predict who will develop mitral valve disease and initiate treatment to prevent it,” Petracek said.
Byrne said the VICTR grant is a stepping stone for Absi and Su to obtain national support for further research on valve disease.
“This grant is just a start. Translational research cannot be done by one single individual; it is a collaborative venture,” Byrne said. “We are working together to personalize each patient’s treatment and outcome.”